
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. is advancing its clinical development pipeline, particularly with its lead candidate rhenium (186Re) obisbemeda, which demonstrates promising results in treating central nervous system cancers, showing a 76% radiographic response rate and a mean overall survival of 9 months. Revenue projections for CNSide indicate gradual growth, with expectations of $1 million in 2025 increasing to $38 million by 2032, as the company expands its reach and more users adopt the diagnostic. Additionally, the recent $18 million grant from the Cancer Prevention and Research Institute of Texas underscores Plus Therapeutics's commitment to innovative cancer treatments and supports a long-term positive outlook for the company's financial health and product development trajectory.
Bears say
The negative outlook on Plus Therapeutics Inc. is primarily driven by several factors, including the risks associated with the failure of its product candidates, such as rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials. Additionally, challenges in obtaining regulatory approval for commercial sale, securing suitable reimbursement, and facing increased competition further threaten the company's prospects. The recent equity raise has also led to dilution, contributing to the revised 12-month price target being lowered from $3.00 to $2.00 per diluted share.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares